Literature DB >> 25788242

Pharmacokinetics of UC781-loaded intravaginal ring segments in rabbits: a comparison of polymer matrices.

Meredith R Clark1, Patrick F Kiser, Andrew Loxley, Christopher McConville, R Karl Malcolm, David R Friend.   

Abstract

UC781 is a potent and poorly water-soluble nonnucleoside reverse transcriptase inhibitor being investigated as a potential microbicide for preventing sexual transmission of HIV-1. This study was designed to evaluate the in vivo release and pharmacokinetics of UC781 delivered from matrix-type intravaginal ring segments in rabbits. Three polymer matrices (polyurethane, ethylene vinyl acetate copolymer, and silicone elastomer) and two drug loadings (5 and 15 mg/segment) were evaluated in at least one of two independent studies for up to 28 days in vivo. Inter-study comparison of in vivo release, vaginal tissue, and plasma concentrations for similar formulations demonstrated good reproducibility of the animal model. Mean estimates for a 28-day in vivo release ranged from 0.35 to 3.17 mg UC781 per segment. Mean proximal vaginal tissue levels (adjacent to the IVR segment) were 8-410 ng/g and did not change significantly with time for most formulations. Distal vaginal tissue levels of UC781 were 6- to 49-fold lower than proximal tissue levels. Mean UC781 plasma levels were low for all formulations, at 0.09-0.58 ng/mL. All formulations resulted in similar UC781 concentrations in vaginal tissue and plasma, except the low loading polyurethane group which provided significantly lower levels. Loading dependent release and pharmacokinetics were only clearly observed for the polyurethane matrix. Based on these results, intravaginal ring segments loaded with UC781 led to vaginal tissue concentrations ranging from below to approximately two orders of magnitude higher than UC781's EC50 under in vitro conditions (2.8 ng/mL), with little influence by polymer matrix or UC781 loading. Moreover, these findings support the use of rabbit vaginal pharmacokinetic studies in preclinical testing of microbicide intravaginal rings.

Entities:  

Year:  2011        PMID: 25788242     DOI: 10.1007/s13346-011-0032-4

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  27 in total

1.  Physicochemical characterization of solid dispersions of the antiviral agent UC-781 with polyethylene glycol 6000 and Gelucire 44/14.

Authors:  F Damian; N Blaton; L Naesens; J Balzarini; R Kinget; P Augustijns; G Van den Mooter
Journal:  Eur J Pharm Sci       Date:  2000       Impact factor: 4.384

2.  Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Authors:  Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor
Journal:  Science       Date:  2010-07-19       Impact factor: 47.728

3.  Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone.

Authors:  Hans-Joachim Ahrendt; Israel Nisand; Carlo Bastianelli; Maria Angeles Gómez; Kristina Gemzell-Danielsson; Wolfgang Urdl; Birgit Karskov; Luc Oeyen; Johannes Bitzer; Geert Page; Ian Milsom
Journal:  Contraception       Date:  2006-09-27       Impact factor: 3.375

4.  Blocking of cell-free and cell-associated HIV-1 transmission through human cervix organ culture with UC781.

Authors:  Ariela Zussman; Liliana Lara; Humberto H Lara; Zvi Bentwich; Gadi Borkow
Journal:  AIDS       Date:  2003-03-28       Impact factor: 4.177

5.  Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir.

Authors:  Todd J Johnson; Kavita M Gupta; Judit Fabian; Theodore H Albright; Patrick F Kiser
Journal:  Eur J Pharm Sci       Date:  2009-12-01       Impact factor: 4.384

6.  Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virus.

Authors:  J Balzarini; W G Brouwer; D C Dao; E M Osika; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

Review 7.  Controlled-release vaginal ring drug-delivery systems: a key strategy for the development of effective HIV microbicides.

Authors:  Susan M Fetherston; R Karl Malcolm; A David Woolfson
Journal:  Ther Deliv       Date:  2010-12

8.  Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women.

Authors:  Annalene Nel; Shanique Smythe; Katherine Young; Karl Malcolm; Clare McCoy; Zeda Rosenberg; Joseph Romano
Journal:  J Acquir Immune Defic Syndr       Date:  2009-08-01       Impact factor: 3.731

9.  A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging.

Authors:  L Henriksson; M Stjernquist; L Boquist; I Cedergren; I Selinus
Journal:  Am J Obstet Gynecol       Date:  1996-01       Impact factor: 8.661

10.  In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides.

Authors:  Yven Van Herrewege; Jo Michiels; Jens Van Roey; Katrien Fransen; Luc Kestens; Jan Balzarini; Paul Lewi; Guido Vanham; Paul Janssen
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

View more
  6 in total

1.  An intravaginal ring for the simultaneous delivery of multiple drugs.

Authors:  Marc M Baum; Irina Butkyavichene; Joshua Gilman; Sean Kennedy; Etana Kopin; Amanda M Malone; Cali Nguyen; Thomas J Smith; David R Friend; Meredith R Clark; John A Moss
Journal:  J Pharm Sci       Date:  2012-05-22       Impact factor: 3.534

2.  Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring.

Authors:  John A Moss; Amanda M Malone; Thomas J Smith; Sean Kennedy; Etana Kopin; Cali Nguyen; Josh Gilman; Irina Butkyavichene; Kathleen L Vincent; Massoud Motamedi; David R Friend; Meredith R Clark; Marc M Baum
Journal:  Antimicrob Agents Chemother       Date:  2011-11-28       Impact factor: 5.191

3.  Intravaginal flux controlled pump for sustained release of macromolecules.

Authors:  Ryan S Teller; Rachna Rastogi; Todd J Johnson; Michael J Blair; Robert W Hitchcock; Patrick F Kiser
Journal:  Pharm Res       Date:  2014-05-02       Impact factor: 4.200

4.  Vaginal rings for delivery of HIV microbicides.

Authors:  R Karl Malcolm; Susan M Fetherston; Clare F McCoy; Peter Boyd; Ian Major
Journal:  Int J Womens Health       Date:  2012-11-20

5.  Engineering a segmented dual-reservoir polyurethane intravaginal ring for simultaneous prevention of HIV transmission and unwanted pregnancy.

Authors:  Justin T Clark; Meredith R Clark; Namdev B Shelke; Todd J Johnson; Eric M Smith; Andrew K Andreasen; Joel S Nebeker; Judit Fabian; David R Friend; Patrick F Kiser
Journal:  PLoS One       Date:  2014-03-05       Impact factor: 3.240

Review 6.  In Vitro Methods for Evaluating Drug Release of Vaginal Ring Formulations-A Critical Review.

Authors:  Katharina Tietz; Sandra Klein
Journal:  Pharmaceutics       Date:  2019-10-16       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.